Our Organization Souvien Therapeutics, Ltd.
Our Organization Souvien Therapeutics, Ltd.
Lavender Swirl Background
Partner

Souvien Therapeutics, Ltd.

Dementia and neurodegenerative conditions are a tremendous burden on our healthcare system and economy.



Souvien Therapeutics, Ltd. is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

Souvien is founded on the pioneering research of Dr. Li-Huei Tsai, PhD, the Director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Dr. Stephen Haggarty, PhD, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital.

The development plan is based on a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. The goal is to use that knowledge, and the greatly evolving understanding of aging, to bring new drugs into human trials.

In the News

Juvenescence

Juvenescence Appoints CEO for Souvien & Epigenetic Division

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team.

June 10, 2020

Read More
Juvenescence

Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments

Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.

May 27, 2019

Read More

Contact Us

We are here to help answer any questions you might have.